{'52WeekChange': 1.2814813,
 'SandP52WeekChange': None,
 'address1': '55 Collins Street',
 'address2': 'Level 38',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.5,
 'askSize': 800,
 'averageDailyVolume10Day': 293312,
 'averageVolume': 682603,
 'averageVolume10days': 293312,
 'beta': 2.687209,
 'beta3Year': None,
 'bid': 12.47,
 'bidSize': 800,
 'bookValue': 4.57,
 'category': None,
 'circulatingSupply': None,
 'city': 'Melbourne',
 'companyOfficers': [],
 'country': 'Australia',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.605,
 'dayLow': 12.195,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -23.165,
 'enterpriseToRevenue': 40.42,
 'enterpriseValue': 1350913792,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '61 3 9639 6030',
 'fiftyDayAverage': 12.380857,
 'fiftyTwoWeekHigh': 20.57,
 'fiftyTwoWeekLow': 3.12,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 84350149,
 'forwardEps': -0.31,
 'forwardPE': -40.29032,
 'fromCurrency': None,
 'fullTimeEmployees': 83,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.02095,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1561852800,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/mesoblast.com',
 'longBusinessSummary': 'Mesoblast Limited, a biopharmaceutical company, '
                        'develops and commercializes allogeneic cellular '
                        'medicines. The company offers products in the areas '
                        'of cardiovascular, spine orthopedic disorder, '
                        'oncology, hematology, and immune-mediated and '
                        'inflammatory diseases. Its proprietary regenerative '
                        'medicine technology platform is based on specialized '
                        'cells known as mesenchymal lineage adult stem cells. '
                        "The company's products under the Phase III clinical "
                        'trials include MSC-100-IV for steroid refractory '
                        'acute graft versus host disease; MPC-150-IM for '
                        'advanced heart failure; and MPC-06-ID for chronic low '
                        'back pain due to degenerative disc disease. It is '
                        'also developing MPC-300-IV that is in Phase II '
                        'clinical trials for the treatment of biologic '
                        'refractory rheumatoid arthritis, diabetic kidney '
                        'diseases, and type 2 diabetic nephropathy. It '
                        'operates in the United States, Australia, Singapore, '
                        'the United Kingdom, and Switzerland. Mesoblast '
                        'Limited has strategic partnerships with Tasly '
                        'Pharmaceutical Group to offer MPC-150-IM for heart '
                        'failure and MPC-25-IC for heart attacks in China; JCR '
                        'Pharmaceuticals Co. Ltd. for the treatment of wound '
                        'healing in patients with epidermolysis bullosa; and '
                        'Gr√ºnenthal to develop and commercialize cell therapy '
                        'for the treatment of chronic low back pain. The '
                        'company was founded in 2004 and is headquartered in '
                        'Melbourne, Australia.',
 'longName': 'Mesoblast Limited',
 'market': 'us_market',
 'marketCap': 1496014720,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_20356678',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -66056000,
 'nextFiscalYearEnd': 1625011200,
 'open': 12.36,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.39,
 'phone': '61 3 9639 6036',
 'previousClose': 12.32,
 'priceHint': 2,
 'priceToBook': 2.7330415,
 'priceToSalesTrailing12Months': 44.761375,
 'profitMargins': -1.9764199,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.605,
 'regularMarketDayLow': 12.195,
 'regularMarketOpen': 12.36,
 'regularMarketPreviousClose': 12.32,
 'regularMarketPrice': 12.36,
 'regularMarketVolume': 184319,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 116790000,
 'sharesPercentSharesOut': 0.010199999,
 'sharesShort': 1193967,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 838688,
 'shortName': 'Mesoblast Limited',
 'shortPercentOfFloat': None,
 'shortRatio': 2.36,
 'startDate': None,
 'state': 'VIC',
 'strikePrice': None,
 'symbol': 'MESO',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.64,
 'twoHundredDayAverage': 9.615684,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'cb226b99-e7ae-3bd6-b05f-2314b416f7a7',
 'volume': 184319,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.mesoblast.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '3000'}